Deamination intensity profiling of human APOSEC3 protein activity along the near full-length genomes of HIV-1 and MoMLV by HyperHRM analysis

被引:8
作者
Belanger, Kasandra [1 ]
Savoie, Mathieu [1 ]
Aydin, Halil [1 ]
Renner, Tyler Milston [1 ]
Montazeri, Zahra [2 ]
Langlois, Marc-Andre [1 ]
机构
[1] Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada
[2] Univ Ottawa, Fac Med, Dept Epidemiol & Community Med, Ottawa, ON K1H 8M5, Canada
基金
加拿大健康研究院;
关键词
APOBEC3; Hypermutation; Cytidine deamination; HIV; Moloney murine leukemia virus; HUMAN-IMMUNODEFICIENCY-VIRUS; APOBEC3 CYTIDINE DEAMINASES; RESOLUTION MELTING ANALYSIS; DRUG-RESISTANCE; DNA;
D O I
10.1016/j.virol.2013.10.008
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Enzymatic deamination of cytidines in DNA is an intrinsic component of antibody maturation and retroviral resistance, but can also be a source of HIV drug resistance and cancer-causing mutations. Here, we developed a high-throughput method based on high resolution melt (HRM) analysis called HyperHRM that can screen genomic DNA for rare hypermutated proviral sequences and accurately quantify the number of C-to-T or G-to-A mutations in each sequence. We demonstrate the effectiveness of the approach by profiling in parallel the intensity of the DNA mutator activity of all seven human APOBEC3 proteins on the near full-length sequence of HIV-1 and the Moloney murine leukemia virus. Additionally, HRM was successfully used to identify hypermutated proviral sequences in peripheral blood mononuclear cells from an HIV-1 patient. These results exemplify the effectiveness of HRM-based approaches for hypermutation quantification and for the detection of hypermutated DNA sequences potentially associated with disease or retroviral drug resistance. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:168 / 175
页数:8
相关论文
共 25 条
  • [1] Alexandrov L.B., 2013, NATURE IN PRESS
  • [2] Belanger K., 2013, NUCL ACIDS IN PRESS
  • [3] Burns M.B., 2013, NAT GENET IN PRESS
  • [4] APOBEC3B is an enzymatic source of mutation in breast cancer
    Burns, Michael B.
    Lackey, Lela
    Carpenter, Michael A.
    Rathore, Anurag
    Land, Allison M.
    Leonard, Brandon
    Refsland, Eric W.
    Kotandeniya, Delshanee
    Tretyakova, Natalia
    Nikas, Jason B.
    Yee, Douglas
    Temiz, Nuri I. A.
    Donohue, Duncan E.
    McDougle, Rebecca M.
    Brown, William L.
    Law, Emily K.
    Harris, Reuben S.
    [J]. NATURE, 2013, 494 (7437) : 366 - 370
  • [5] Conticello Silvestro G, 2007, Adv Immunol, V94, P37, DOI 10.1016/S0065-2776(06)94002-4
  • [6] The AID/APOBEC family of nucleic acid mutators
    Conticello, Silvestro G.
    [J]. GENOME BIOLOGY, 2008, 9 (06)
  • [7] E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure
    Fourati, Slim
    Malet, Isabelle
    Lambert, Sidonie
    Soulie, Cathia
    Wirden, Marc
    Flandre, Philippe
    Fofana, Djeneba B.
    Sayon, Sophie
    Simon, Anne
    Katlama, Christine
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    [J]. AIDS, 2012, 26 (13) : 1619 - 1624
  • [8] Haché G, 2006, AIDS REV, V8, P148
  • [9] The HIV-1 Central Polypurine Tract Functions as a Second Line of Defense against APOBEC3G/F
    Hu, Chunling
    Saenz, Dyana T.
    Fadel, Hind J.
    Walker, William
    Peretz, Mary
    Poeschla, Eric M.
    [J]. JOURNAL OF VIROLOGY, 2010, 84 (22) : 11981 - 11993
  • [10] Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity To Restrict Vif-Deficient HIV-1
    Hultquist, Judd F.
    Lengyel, Joy A.
    Refsland, Eric W.
    LaRue, Rebecca S.
    Lackey, Lela
    Brown, William L.
    Harris, Reuben S.
    [J]. JOURNAL OF VIROLOGY, 2011, 85 (21) : 11220 - 11234